

Special Issue

Vaccination Status during Pregnancy and Childhood

Message from the Guest Editors

Despite the efforts to implement vaccination programs, new challenges continually arise to defeat the objectives of controlling and eliminating communicable diseases: e.g. new diseases with no vaccine available, public skepticism about vaccination, poor immunization coverage, etc. In this context, pregnant women and children usually represent risk groups with worse outcomes than the average population. In addition, for ethical reasons, they are usually left out of clinical trials for new vaccines, as it has been the case of COVID-19. The aim of this issue is to publish research about vaccination in pregnancy and childhood, using a broad perspective. From antigen discovery and preclinical studies to immunoepidemiological analyses of current vaccination programs, this issue intends to cover all communicable diseases with high morbidity and/or mortality for mothers-to-be, newborns, infants and children.

Guest Editors

Dr. Pilar Requena

Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain

Prof. Dr. Ester Leno Duran

Department of Obstetrics and Gynecology, University of Granada, Granada, Spain

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/88387

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).